Changes in Hong Kong stocks | Gloria Ying (06821) rose more than 5% in the afternoon, the gross margin of emerging businesses increased significantly in the first half of the year, and is expected to accelerate growth due to fulfillment of orders during the year

The Zhitong Finance App learned that Gloria Ying (06821) rose more than 5% in the afternoon. As of press release, it had risen 5.53% to HK$130.4, with a turnover of HK$120 million.

According to the news, Gloria Ying recently disclosed its 2026 interim results. BOC International indicated that the company's 1H26 revenue and adjusted net profit both increased 13% year over year. The company's revenue from emerging businesses surged 72%, and gross margin increased significantly to 32.5%; revenue from chemical macromolecules, biopharmaceutical CDMO and formulation businesses increased by 94%/123%/51%. Management maintains the guidance of 19-22% revenue growth for the whole year.

BOC International said that Gloria Ying's 1H26 orders surged 54% year-on-year, with 8M26 signing +55% of new orders. Management expects about 85% of on-hand orders to be realized as revenue in 2H26-2027. Among them, orders for chemical macromolecules were +164%, related projects and PPQ projects in the field of peptide weight loss increased to 25/8, and oligonucleotide and payload-linker projects progressed rapidly to the later/PPQ stage. The company raised its annual capital expenditure guidelines to 26-2.8 billion yuan, and will further increase to 3 billion yuan in 2027, focusing on chemical macromolecules and biomacromolecules.